Lviv clinical bulletin 2013, 3(3): 8-13

https://doi.org/10.25040/lkv2013.03.008

Benfotiamine and Long-Chain Omega-3 and Omega-6 Polyunsaturated Fatty Acids in Treatment of Cardiac Autonomic Neuropathy in Patients with Type 2 Diabetes Mellitus

Posted onAuthorAdminЗалишити коментар / Leave a comment

V. Serhiyenko, O. Serhiyenko

Danylo Halytsky Lviv National Medical University

Introduction. The cardiovascular form of diabetic autonomic neuropathy (DANP) in patients with type 2 diabetes mellitus (DM), is characterized by the damage of the nerve fibers of the parasympathetic and sympathetic parts of the autonomic nervous system, and is considered to be one of the main causes of cardiac arrhythmias, an independent risk factor of cardiovascular mortality. Therefore, the problem of prevention and treatment of DANP is especially relevant. The pathogenetic treatment of DANP includes rational nutrition and physical activity, optimization of glycemic control, treatment of dyslipoproteinemia (DLP), correction of metabolic disorders of the myocardium, prevention and treatment of thrombosis, use of aldose reductase inhibitors, γ-linolenic acid, acetyl-L-carnitine, antioxidants, in particular α-lipoic acid (α-LA), long-chain ω-3 and ω-6 polyunsaturated higher fatty acids, vasodilators, fat-soluble vitamin B1, aminoguanidine, substitution treatment with myoinozitol, growth factors, etc.

Aim. To evaluate the efficacy of treatment with benfotiamine, long-chain ω-3 and ω-6 polyunsaturated higher fatty acids of the cardiovascular form of diabetic autonomic neuropathy in patients with type II DM.

Materials and methods. Тhe study involved 59 patients with type 2 diabetes mellitus (DM) and cardiovascular autonomic neuropathy (CAN), aged 50–59 years, with a disease duration of 1–6 years and HbA1c index (7.1 ± 0.6 %). Patients with type 2 DM and CAN were allocated to four treatment groups: patients of the 1st group received traditional hypoglycemic therapy (n=15); to patients from the 2nd group (n = 21), in addition to the standard treatment, was prescribed 1 capsule of “Omacor®” daily; to the 3rd group of patients (n = 12) – benfotiamine 300.0 mg per day; to the 4th group (n = 11) – “Omacor®” (1 capsule/day) in combination with benfotiamine 300.0 mg per day.

Results. It has been established, that combined prescription of “Omacor ®” and benfotiamine is accompanied by more significant positive changes in HDL, triglycerides and leptin levels comparing to control group and group treated with benfotiamine, but no statistically significant changes compared to the therapy with “Omacor®” have been obtained. Application of this combination was accompanied by more significant positive changes in IRI, hsCRP and TNF-α levels compared to other groups.

Conclusions. The efficacy of combined therapy with “Omacor®” and benfotiamine is not determined by the improved compensation of type 2 DM, but is the result of direct effect of pharmacological agents on the investigated metabolic parameters.

References

  1. Sergienko OO, Sergienko VO. Autonomic Cardiac Neuropathy in Patients with Type 2 Diabetes Mellitus: Classification, Clinical Manifestations, Diagnosis: methodical recommendations. Kyiv: Ukrmedpatentinform of Ministry of Health of Ukraine, 2011. 22 p. (Ukrainian)
  2. Korkushko OV, Shatilo VB, Ishchuk VA. The Use of Omega-3 Polyunsaturated Fatty Acids for the Normalization of Endothelial Function and Rheological Parameters of Blood in the Pathology of the Cardiovascular System. Ukrainian Medical Journal. 2010; 2: 46-49. (Russian)
  3. Lapach SN. Statistical Methods in Biomedical Research Using Excel. Кyiv: Morion, 2000. 320 p. (Russian)
  4. Mitchenko EI, Romanov VY, Chulaevskaya IV. The Role and Place of Omega-3 Polyunsaturated Fatty Acids in the Diet of Patients with Metabolic Syndrome. Ukrainian Medical Journal. 2011; 4: 57-59. (Russian)
  5. Murashko NK, Kravchun PP. Benfotiamine – a New Way to Correct the Endothelial Dysfunction in the Treatment of Cardiovascular Diseases. Medications of Ukraine. 2009; 5 (131): 87-91. (Russian)
  6. Sergienko VO. Dislipoproteinemias in Type 2 Diabetes Mellitus: the Main Areas of Treatment (a Review of Literature and Own Research). Journal NAMS of Ukraine. 2012; 18 (2): 205-216. (Ukrainian)
  7. Skrypnyk NV, Gryb VA, Didushko OM. Peculiarities of the Pathogenesis and Treatment of Diabetic Autonomic Neuropathy (Review of Literature). Medications of Ukraine. 2012; 2 (158): 10-14. (Ukrainian)
  8. Bowman L, Haynes R, Armitage J. A pandomized controlled trial of aspirin and of omega-3 fatty acids supplementation for the primary prevention of vascular disease in people with diabetes. Diabet Vasc Dis Res. 2008;5(4):357-358.
  9. De Roos B, Mavrommatis Y, Brouwer IA. Long-chain n-3 polyunsaturated fatty acids: new insights into mechanisms relating to inflammation and coronary heart disease. Br J Pharmacol. 2009;158(2):413-428. https://doi.org/10.1111/j.1476-5381.2009.00189.x
  10. Tesfaye S, Boulton AJ, Dyck PJ, Freeman R, Horowitz M, Kempler P et al. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care. 2010;33(10):2285-2293. https://doi.org/10.2337/dc10-1303
  11. Rizza S, Tesauro M, Cardillo C, Galli A, Iantorno M, Gigli F et al. Fish oil supplementation improves endothelial function in normoglycemic offspring of patients with type 2 diabetes. Atherosclerosis. 2009;206(2):569-574. https://doi.org/10.1016/j.atherosclerosis.2009.03.006
  12. Kandasamy N, Joseph F, Goenka N. The role of omega-3 fatty acids in cardiovascular disease, hypertriglyceridaemia and diabetes mellitus. Br J Diabet. Vasc Dis. 2008;8(3):121-128.
  13. Schiano V, Laurenzano E, Brevetti G, De Maio JI, Lanero S, Scopacasa F et al. Omega-3 polyunsaturated fatty acid in peripheral arterial disease: effect on lipid pattern, disease severity, inflammation profile, and endothelial function. Clin Nutr. 2008;27(1):241-247. https://doi.org/10.1016/j.clnu.2007.11.007
  14. Pop-Busui R. Cardiac autonomic neuropathy in diabetes: a clinical perspective. Diabetes Care. 2010;33(2):434-441. https://doi.org/10.2337/dc09-1294
  15. Serhiyenko L, Serhiyenko A, Serhiyenko V. Nicotinamide and alpha-lipoic acid in the treatment of cardiovascular autonomic neuropathy in Type 2 diabetes mellitus patients. Endocrine Abstracts. 2007;14:61-62.
  16. Vinik AI, Maser RE, Ziegler D. Neuropathy: the crystal ball for cardiovascular disease? Diabetes Care. 2010;33(7):1688-1690. https://doi.org/10.2337/dc10-0745
  17. Ziegler D. Can diabetic polyneuropathy be successfully treated? MMW Fortschr Med. 2010;152(9):64-68. https://doi.org/10.1007/BF03366224